Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 3/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.35 |
| ▸ | AKT2 | P31751 | 2/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1236387 | 0.82 | — | — | |
| SCHEMBL16869453 | 0.79 | NOS2 (0.36) | KCNH2LMNAAPEX1PMP22NOS2 | |
| SCHEMBL18272519 | 0.78 | NOS2 (0.38) | KCNH2LMNAAPEX1PMP22NOS2 | |
| SCHEMBL18291459 | 0.77 | KCNH2 (0.42) | KCNH2LMNAAPEX1PMP22NOS2 | |
| SCHEMBL23031949 | 0.77 | KCNH2 (0.42) | KCNH2LMNAAPEX1PMP22NOS2 | |
| SCHEMBL84454 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL20897673 | 0.75 | — | — | |
| SCHEMBL6344963 | 0.75 | — | — | |
| SCHEMBL24050461 | 0.74 | KCNH2 (0.39) | KCNH2LMNAAPEX1PMP22NOS2 | |
| SCHEMBL23586437 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200262818-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-08-20 | — | — | US | disclosed |
| EP-3110418-B1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2019-11-06 | — | — | EP | disclosed |
| EP-3230273-A1 | 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG | Cancer Research Technology Ltd (GB) | 2017-10-18 | — | — | EP | disclosed |
| WO-2016092326-A1 | 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200262818-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | CFD, TFPI, CFH | KCNH2 2778/4885LMNA 2383/4885APEX1 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.